BIO INVESTOR FORUM -...
21
17 OCTOBRE 2017 TSX-V: TBP OTC: TBPMF BIO INVESTOR FORUM PRESENTATION Bob Béchard VP – Business Development TSX-V: TBP OTC: TBPMF
-
Upload
duongkhanh -
Category
Documents
-
view
219 -
download
2
Transcript of BIO INVESTOR FORUM -...
17OCTOBRE2017
TSX-V:TBP OTC:TBPMF
BIOINVESTORFORUM
PRESENTATION
BobBéchardVP– BusinessDevelopment
TSX-V:TBP OTC:TBPMF
ForwardLookingStatementsThis presentation contains certain forward-looking statements that may involve a number of risks and uncertainties.Actual events or results could differ materially from the expectations and projections of Tetra Bio-Pharma Inc. Theinformation contained in this presentation has not been approved or disapproved by any Securities Commission in Canada,The Securities and Exchange Commission in the US or other regulatory body. Except for statements of historical fact relatingto the Company, certain information contained herein constitutes "forward-looking statements". Forward-looking statementsare frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate" and other similarwords, or statements that certain events or conditions "may" or "will" occur.
Forward-looking statements are based on the opinions and estimates of management at the date the statements are made,and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differmaterially from those projected in the forward-looking statements. These factors include the inherent risks involved in thedevelopment of botanical based pharmaceuticals or medical devices regulated by Health Canada, the FDA or otherinternational regulatory agencies, product obsolescence, the uncertainties involved in patent defense and complexities andtimelines associatedwith product approvals in multiple jurisdictions.
The possibility of project cost overruns or unanticipated costs and expenses, uncertainties relating to the availability andcosts of financing needed in the future and other factors. Circumstances or management's estimates or opinions couldchange. The reader is cautioned not to place undue reliance on forward-looking statements. Except as required by law, weundertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information,future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipatedevents. Neither we nor any of our representatives make any representation or warranty, express or implied, as to theaccuracy, sufficiencyor completeness of the information in this presentation.
Neither we nor any of our representatives shall have any liability whatsoever, under contract, tort, trust or otherwise,to you or any person resulting from the use of the information in this presentation by you or any of your representatives orfrom omissions from the information in this presentation.
2
Tetra Bio-Pharma is focused on becoming THE Bio-Pharmaceutical leader in cannabinoid-based drug discovery & development,
with a clinical program aimed at bringing novel drugs and treatments to patients and their healthcare providers
FromStart-UptoExplosiveGrowth
2
§TetraFounded 2015
TSX-V(TBP) CAD$0.73
OTCQB(TBPMF) US$0.52
MarketCapitalization US$74MM
SharesIssued 118.8MM
SharesFullyDiluted 132.5MM
InsiderOwnership 9.4%
Cash/Equivalent(AsofSept1st,2017) CAD$2.2M
G&AcashBurnRate/Month CAD$100K
GlobalLeaderinCannabinoid-basedDrugDiscovery
3
Pharmaceuticalresearch&
developmentofcannabinoid-based
drugs
RESEARCH
CommercializationofmedicalcannabisunderACMPRandcannabinoid-basedprescriptiondrugs
PHARMACEUTICALCommercializationofcannabinoid-basedproductsforthe
naturalhealthproductmarket
(self-care)
RETAIL
5
REPORT: TheCannabisBiotech/PharmaMarketCouldSurpass$20Billionby2020ViridianCapitalAdvisors|Wednesday,02December201505:43 (EST)
WhyCannabis/Cannabinoids?• TremendousAmountofAnecdotalEvidenceThatitWorks
inChronicPain,PTSD,ChemoInducedNauseaandVomiting,MS,Epilepsyetc.
• AmericanAcademiesofScienceStatedThereisSubstantialEvidenceSupportingitsUseinChronicPain,ChemoInducedNausea&VomitingandMS
• 1/3ofAmericanssufferfromChronicPain
• 1/3ofUSChronicPainSufferersUseOpioids
• ThereisTremendousPotentialforOpioidSparing
• PotentialForTreatingAddictions
6
WhatMakesTetraBPanExcitingInvestment?
7
Providingpharmaceuticalrelevancethroughclinicalsupportforcannabinoid-baseddrugstotreatavarietyofhuman andveterinary diseases
Developingclinicallysupportedmedicalcannabis
RobustPipelineUsingMultipleFormsofDeliveryonaVarietyofIndications
Predictedcannabis-baseddrugswillreplacedrugswithtoxicsideeffectprofiles(i.e.opioids)
TremendousAmountofAnecdotalEvidence….Cannabinoidsdowork!
Notthesameinvestmentriskasanewchemicalentity
Pharmaceutical– Tetra’sProductPipeline
8
PPP001– PrescriptionDriedCannabis
9
§ Firstsmokablecannabisforadvancedcancerpain
§ Aphria:API&StrategicPartner§ SuccessfullycompletedPhaseI– Preparing
launchPhaseIIIclinicaltrialQ4/17§ SigningcommercialpartnerQ4/18§ AnticipatedfilingofNDAQ4/18§ MarketPotentialN.A.:4Mcancerpatients&
painmarket$5billionaccordingtoGlobalPainManagement
PPP002– Dronabinol XLTablet
10
§ Buccallyabsorbedmuco-adhesivetablet
§ AdvantageoverapprovedsyntheticTHC:§ SustainedTHCrelease,reducingsideeffectsandincreasingdrugstability
§ PhaseIcompleted:Safetysignificantlysuperior
§ Humanindications– ChemoInducedNauseaandVomitingandpainmarket
§ NextSteps:§ PhaseII– Q1/18§ PhaseIII– Q1/19§ CommercialPartnership– Q1/19§ AnticipatedfilingofNDA- 2020
PPP003– OphthalmicDrugs
11
§ THC:CBDcontainingeyedropstotreatocularpainandinflammation,uveitisanddryeye
§ Pre-clinicalproofofconceptstudiescompleted
§ Non-clinicalsafetytestingphase
§ Firsttargetindication:cornealpainandinflammation
§ NextSteps:§ CTAfilingofPhaseItrial– Q2/18§ AnticipatedfilingofNDA– 2022§ PartnershipbyQ22019
§ PotentialUSAMarket:$3 billionincludespost-opinflammationandallergicconjunctivitisaccordingtoIMS
PPP004– TopicalOintment
12
§ THC:CBD1:1topicalcreamtotreatgeneralneuropathicpain
§ Pre-clinicalstudiesunderway
§ NextSteps:§ CTAfilingforPhaseItrial– Q22018§ AnticipatedfilingofNDA– 2022§ Partnershipsignedby2020
§ PotentialUSAMarket:$2.5billionin2014,overthecountersalesoftopicalanalgesicsaccordingtoIMS
BusinessModel• TypicalBiotechBusinessModel(RX)• ActivelySeekingCommercializationandDevelopment
Partners• Upfronts,MilestonesandRoyalties• OurExpertiseremainsinFindingandDeveloping
CannabinoidBasedProducts,aswellasonfindingthemostEfficientRegulatoryPathwaytoApprovalbyRegulatoryAgencies
• RetailArmusedforSellingCannabinoidBasedSelf-CareProducts
• WillalsobeginSellingMedicinalCannabisunderCDNCompassionateUseProgram
13
Retail– NaturalHealthProducts
14
§ LOIannouncedJuly19,2017withConstanceTherapeuticsforspecializedmedicalcannabisproducts
§ MunchiesBGonegum
§ PainGel– Non-greasypenetratingreliefgel
§ SleepPro– Sleepaidforcasesofrestlessness/nervousness
§ VitallyStressADO– Usedforanxiety,insomnia,dyssomnia
§ VitallyWaterRelax– Usedforanxiety/tensionafteracuteadministration
Partners
TBPlaunchedaHealthResearchChairinCannabisatUNB
Collaborationonstudytodevelopconsumerproductscontainingcannabinoids
Granted TBPwithresearchfundingtocollaboratewMcGill
Ourpartner forPPP001production- ProducerofMedicinalCannabis
Stage1clinical trial - PPP001
QCfirstmedical clinicandresourcecentrespecializing inmedical cannabis.WillperformPhase3clinical trialsofPPP001
15
CompetitiveLandscape
16
GWPharma$GWPHMarketCapitalization:$2.7BUSDGWPharmahas2productsinitspipe lineinstage1andstage3forepilepsy andMS- oneapprovedproduct
INSYSTherapeutics$INSYMarketCapitalization:$549MMUSDIsatraditionalPharmacompanythatwasawardedorphandrugstatusforCBDfortreatmentofGBM-noproductsinClinicalTesting
CaraTherapeutics$CARAMarketCapitalization:$406MUSDR&DonCannabinoid receptors.Utilizingsyntheticcompounds
Zynerba Pharmaceuticals$ZYNEMarketCapitalization:$133MMUSD
DevelopingasyntheticTHCtransdermalpatchaswellasasyntheticCBDgel
Kalytera Therapeutics$KALYMarketCapitalization:$17MMCADPreparingforaPhase2studytoevaluatecannabidiol forthepreventionofGvHD
ExperiencedManagementTeam
17
BernardFortier,MBACEO• Experiencedinmanagement&businessdevelopmentinthebiopharma,specializedmedicalnutrition&medicalfields
• Spent8yearsincommercialrolesatSerono CANincludingNationalSalesManagerinNeurologybusinessunit
• PreviousheadofOrimed Pharma–grewproductdevelopmentfrom3to10productswithin4years
GuyChamberlandCSO• HoldsaM.Sc.andPh.D.degrees,isaMasterHerbalist
• ServedasVPofClinical &RegulatoryAffairsatVicthom Laboratory.
• PreviousVPofRegulatory Affairs&Clinical DevelopmentatAngiogene Inc
• WorkedforCATOResearchLtdandMDSPharmaServicesspecializinginregulatory affairs inareasofdrugs,biologics, medicaldevices,combination productsandbotanicals
BernardLessardCFO• Considerableexperienceasc-suiteexecutiveinlifesciencessectorinstart-ups
• Involvedwithnumerousfinancings,venturecapitalfunds&M&Atransactions
• ExperiencedCFOinriskmanagement&governance
• StrongpoliticalconnectionstoQuebecGovernment
• HoldsaMBA,CPA,CMA
Anne-SophieCourtoisVP,Marketing&communication• 10yearsinternationalexperienceinpharmaceuticalmarketing
• PreviousDirectorofMarketing&ScientificAffairsatJampPharma&Orimed Pharma–grewsales150%in4years
• Managedmarketinglaunchof120genericproducts&10brandedproductsinCanada
• Isaveterinarydoctor
DenisCourchesneVP,Sales• 25years’salesandmanagementexperienceintheretailenvironmentworkingforvariouscompaniessuchasEvianSpringWater(Danone)andPfizer
• Last15years,hasworkied inboththepharmacyandhealthfoodchannelswherehesuccessfullyheldpositionsinQuebecasNationalSalesManager
BobBechardVP,Finance&BD• 12-yeartermatRBCasaseniorventurecapitalist, hemadenumerousinvestments,satontheboardsofmorethan25lifesciencecompaniesandwasactivelyinvolved inthenegotiation ofnumerousstrategicalliances,partnerships, andoutright salestobothpharmaceutical andbiotechcompanies
StrongBoardofDirectors
18
§ AndreRancourt– Chairman&DirectorHighlyexperiencedinmanagement,start-up&commercialstrategiesformanyfieldsincluding human&animalnaturalhealthproducts
§ BernardFortierCEOofTetraBioPharma
§ RobertBrouillette – Bareau duQuebec,LL.B.,B.Sc.A. - DirectorCurrentlyPartneratBrouillette &Partners.Heisaspecializedlawyer,civilengineer,patent&trade-markagent
§ BillCheliak- Ph.D.- DirectorCurrentlyCEOofPanag Pharma,aCanadianbio-techfocusedonthedevelopmentofnovelcannabinoidbasedformulations forthetreatmentofpain&inflammation
§ CarlMerton- CA,CPA,FCBV– DirectorCurrentlyCFOofAphria,oneofCanada’slowestcostproducers, produces, suppliesandsellsmedicalcannabis
UpcomingMilestones
19
BuildingTetraasthegloballeaderincannabinoid-baseddrugdiscoveryanddevelopment
§ PPP001 StartPhIIIstudyQ42017§ PPP002 Start Ph IIstudyQ12018§ PPP003 Start PhIstudyQ22018§ PPP004 Start PhIstudyQ22018
§ PPP001 CommercialpartnershipQ42018
Focusedonacceleratedexecution&committedtobuildingshareholdervalue
2017-10-19 21
